X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Castor Launches CRO Partnership Program to Increase Adoption of Decentralized Clinical Trials

    Catalent acquires cell and gene therapy-focused MaSTherCell for $315m

    Cytiva and NecstGen form strategic collaboration to accelerate development of cell and gene therapies

    Astrazeneca Says Covid-19 Long-Acting Antibody Combination AZD7442 Rapidly Advances Into Phase III Clinical Trials

    Valneva and Pfizer Report Further Positive Phase 2 Data for Lyme Disease Vaccine Candidate

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    BioMed X Institute and Merck KGaA, Darmstadt, Germany, Extend Collaboration in Oncology

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma's VP3 Nasal Spray System

    New Combination Product for Symptoms of Seasonal Allergic Rhinitis Approved by US FDA with Aptar Pharma’s VP3 Nasal Spray System

    Cryoport and Cell Matters Enter into Strategic Partnership

    Cryoport and Cell Matters Enter into Strategic Partnership

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Evotec enters iPSC-based drug discovery partnership with Boehringer Ingelheim in ophthalmology

    Gilead Announces Results From Phase 3 Trial of Remdesivir in Patients With Moderate COVID-19

    Gilead Sciences Announces FDA Approval of Veklury for Treatment of Non-Hospitalized Patients at High Risk for COVID-19

    Novavax to Participate in University of Oxford Com-COV2 Study Comparing Mixed COVID-19 Vaccine Combinations

    Australia Therapeutic Goods Administration Grants Provisional Registration for Novavax COVID-19 Vaccine

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

Vifor Pharma, ChemoCentryx Announce Expansion of Avacopan Agreement for Rare Renal Diseases

Yuvraj_pawp by Yuvraj_pawp
15th February 2017
in Research & Development

Vifor Pharma, a company of the Galenica Group, and ChemoCentryx, Inc. announced that Vifor Pharma has gained rights to commercialize avacopan in Asia, including Japan and the Middle East.

ChemoCentryx retains all rights in the United States and China.Avacopan (CCX168) is an orally-administered inhibitor of the complement 5a receptor (C5aR) and is currently in Phase III development for rare renal diseases.

The expanded agreement effectively gives Vifor Pharma rights to commercialize avacopan for orphan and rare renal diseases in all markets outside the United States and China, building on the original licensing agreement signed in May 2016.

ChemoCentryx will receive an upfront cash commitment of USD 20 million in return for the new rights, plus tiered double-digit royalties on potential net sales. This is in addition to the USD 85 million upfront paid under the original May 2016 licensing agreement.

Avacopan is being developed by ChemoCentryx for the treatment of orphan and rare renal conditions including but not limited to anti-neutrophil cytoplasmic auto-antibody (ANCA)-associated vasculitis (AAV). AAV is a systemic disease which most commonly presents as kidney dysfunction.

AAV is currently treated with courses of non-specific immuno-suppressants (cyclophosphamide or rituximab), combined with high-dose corticosteroid administration, which is associated with significant safety issues, including premature death. Avacopan is in Phase III development (the ADVOCATE trial) for the treatment of AAV and is also in development for other orphan and rare renal diseases, including C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome (aHUS).

 

“The expansion of avacopan territory rights with renal care leader Vifor Pharma, and with ChemoCentryx retaining all US and China rights, expertly positions our rare renal disease portfolio for global commercialization,” said Thomas J. Schall, Ph.D., President and CEO of ChemoCentryx. 

“We have now harmonized both the avacopan and the subsequent agreement which we signed in late December for another rare renal asset, CCX140, in our highly productive Kidney Health Alliance with Vifor Pharma. ChemoCentryx also has greater than USD 200 million in proforma reserves, based on our last filings, providing for an ambitious development plan for avacopan and CCX140 in orphan and rare renal diseases. We and Vifor Pharma believe these two unique clinical assets have
the potential to transform lives of those with devastating rare renal diseases, and to build extraordinary value for both of our enterprises.”

 

“The acquisition of global commercialization rights outside the US and China demonstrates our strong belief in the potential of avacopan in a wide range of rare and orphan renal diseases,” said Gianni Zampieri, CEO of Vifor Pharma. “This agreement further strengthens our growing partnership with ChemoCentryx, and underlines our commitment to bring highly innovative therapies to patients with serious renal conditions around the world.”

Vifor Pharma – Media Relations:
Beatrix Benz, Head of Global Communications & Public Affairs
Tel.: +41 58 851 80 16
E-mail: media@viforpharma.com

ChemoCentryx Contacts:
Susan M. Kanaya
Executive Vice President, Chief Financial and Administrative Officer
E-mail: investor@chemocentryx.com

Media:

Denise Powell
Tel.: +1 510.703.9491
E-mail: denise@redhousecomms.com

Investors:

Steve Klass
Burns McClellan
Tel.: +1 212.213.0006
E-mail: sklass@burnsmc.com

Previous Post

Quotient Clinical Acquires Contract Drug Developer, Manufacturer QS Pharma

Next Post

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Related Posts

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines
Press Statements

Exscientia and Sanofi establish strategic research collaboration to develop AI-driven pipeline of precision-engineered medicines

17th January 2022
COVID-19 Impact On Changing Pharma Research And Development
News

COVID-19 Impact On Changing Pharma Research And Development

12th January 2022
immuno-oncology therapies
Drug Development

AbbVie, University of Chicago Extend Research Collaboration to Support Preclinical Oncology Research Through 2025

19th November 2021
GSK drug discovery
Drug Development

Biognosys Launches Next-Generation Blood Biomarker Discovery Solution

19th November 2021
WAPG and Astellas Announce Future Innovator Prize to Help Emerging Biotechs Accelerate Early Drug Discovery and Research Efforts
Drug Development

WAPG and Astellas Announce Future Innovator Prize to Help Emerging Biotechs Accelerate Early Drug Discovery and Research Efforts

22nd October 2021
Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore's Bioprocessing Technology Institute
Drug Development

Waters to Help Accelerate Biologics Production Through Research Collaboration With Singapore’s Bioprocessing Technology Institute

9th July 2021
Next Post

CohBar, Inc. Announces Positive Results from Preclinical NASH Study of its Lead Drug Candidates

Latest News

Envirotainer introduces the RAP for the future - part of the Releye series
Packaging & Logistic

Envirotainer introduces the RAP for the future – part of the Releye series

14th February 2022
United Cargo Meets Growing Demand for Pharmaceuticals with New TempControl Containers
Packaging & Logistic

Opticooler receives technical approval by Japanese major airlines

14th February 2022
Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease
Press Statements

Aptar Pharma Launches HeroTracker Sense, Novel Connected Smart Device for Respiratory Disease

14th February 2022
Johnson & Johnson Prepares to Resume Phase 3 ENSEMBLE Trial of its Janssen COVID-19 Vaccine Candidate in the U.S.
News

Indian Scientists Claim To Design Vaccine For All Variants

9th February 2022
Drones for Delivery To Carry Pharmaceutical Weight Forward
News

Drones for Delivery To Carry Pharmaceutical Weight Forward

9th February 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In